{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Infusion", "query": { "intervention": "Intravenous Infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8238, "total_pages": 824, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T12:04:06.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00333515", "title": "Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Chemical Terrorism", "Chemical Warfare" ], "interventions": [ { "name": "Human Butyrylcholinesterase (HuBChE) derived from human plasma", "type": "DRUG" }, { "name": "Placebo: Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2007-01-01", "completion_date": "2008-08-01", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333515" }, { "nct_id": "NCT05656235", "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Urothelial Carcinoma", "Bladder Cancer", "Urothelial Carcinoma Bladder" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-11-25", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05656235" }, { "nct_id": "NCT02942017", "title": "A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postpartum Depression" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SAGE-547 90 μg/kg/h", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 108, "start_date": "2016-07", "completion_date": "2017-10-11", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 32, "location_summary": "Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02942017" }, { "nct_id": "NCT07148089", "title": "A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Catecholaminergic Polymorphic Ventricular Tachycardia" ], "interventions": [ { "name": "SGT-501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solid Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 18, "start_date": "2026-02-23", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148089" }, { "nct_id": "NCT03912818", "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Squamous Cell Carcinoma", "Bladder Urothelial Carcinoma", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Giant Cells", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Nested Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cystectomy", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-04-10", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912818" }, { "nct_id": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-07-10", "completion_date": "2022-05-31", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 3, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03828448" }, { "nct_id": "NCT00954876", "title": "Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "capecitabine and cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Genomics Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954876" }, { "nct_id": "NCT05221840", "title": "A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Monalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1051, "start_date": "2022-02-07", "completion_date": "2030-07-02", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 33, "location_summary": "San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Stuart", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "New Albany", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05221840" }, { "nct_id": "NCT02470585", "title": "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasm" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placebo to Veliparib", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1140, "start_date": "2015-07-14", "completion_date": "2023-10-05", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02470585" }, { "nct_id": "NCT03066115", "title": "Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypoxia", "Hypercapnia" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Intravenous Catheter", "type": "PROCEDURE" }, { "name": "Transcranial Doppler Ultrasound", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 0, "start_date": "2020-12-01", "completion_date": "2021-12-01", "has_results": false, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-09-03T12:04:06.162Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066115" } ] }